Digging into biopharma’s big buyout areas
Cancer, rare diseases and neurology targets account for a big chunk of biopharma's buyouts, with interest showing no sign of waning.
Rare disease and neurology takeouts tick higher
Biopharma's growing appetite for higher-risk areas prompts a shift in dealmaking strategies, our latest deep dive into M&A data finds.
The year of the small buyout
Biopharma takeouts in the $1-5bn range jumped in 2021, as rising valuations made their mark.
In a quiet year for takeouts, who was buying?
Small and mid-sized developers upped deal-making activity last year, a deep dive into M&A data finds.
UCB makes a rare acquisition
The Belgian group has bolstered its epilepsy offering with a $1.9bn move on Zogenix.
Biopharma’s buyout year ends with a bang
A recent buying spree swells 2021's meagre M&A tally, but the Pfizer-Arena deal could crystallise antitrust concerns.
Biopharma needs a biggie to avoid a down deal year
M&A picked up in the third quarter but overall 2021 has been quiet on the takeover front.
World Lung 2021 – Zepzelca salvages pride from the Atlantis wreckage
Full data from the trial position the Pharmamar/Jazz small-cell lung cancer drug to remain safely on the US market.
